Together, these data indicate that CDK2 inhibition represents a novel therapeutic approach to treat prostate cancers progressing on AR signaling inhibition and exhibiting phenotypic plasticity that includes increased expression and function of MYBL2. The gene discussed is AR; the disease is prostate cancer.